Related Experiment Video

Updated: May 22, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

CCR5 as a potential target in cancer therapy: inhibition or stimulation?

Alicia González-Martin1, Emilia Mira, Santos Mañes

  • 1The Scripps Research Institute, Department of Immunology and Microbial Science, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Anti-Cancer Agents in Medicinal Chemistry
|May 16, 2012
PubMed

Insights

CCR5 chemokine receptor plays a crucial role in tumor immunity and immunotherapy success. Activating CCR5, not inhibiting it, may offer new cancer treatment strategies by enhancing T cell responses.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The chemokine receptor CCR5 and its ligands are implicated in tumor biology.
  • Controversy exists regarding CCR5's role in cancer progression, with conflicting pro- and anti-tumor effects observed.

Purpose of the Study:

  • To investigate the specific role of CCR5 in adaptive anti-tumor immune responses.
  • To explore the potential of targeting CCR5 for cancer immunotherapy and treatment.

Main Methods:

  • Analysis of existing evidence on CCR5 expression and function in various tumor contexts.
  • Hypothesizing the necessity of CCR5 for optimal adaptive immune activation against tumors.
  • Evaluating the implications of CCR5 in the success of immunotherapeutic and conventional treatment strategies.

Main Results:

  • Discrepancies in CCR5's tumor effects may stem from diverse cellular expression and tumor microenvironment contexts.
  • CCR5 is proposed to be essential for effective adaptive immune responses to tumors.
  • CCR5 activation is linked to the success of certain immunotherapies and potentially chemo- and radiotherapy.

Conclusions:

  • CCR5 activation, rather than inhibition, presents a promising therapeutic avenue for cancer treatment.
  • Enhancing CCR5 signaling could improve the efficacy of immunotherapies and conventional cancer treatments by boosting T cell responses.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...